Selection and use of lactic acid bacteria preventing bone loss in mammals
Inventors
Connolly, Eamonn • Britton, Robert Allen • McCabe, Laura Rae
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10232001-B2
Publication Date
2019-03-19
Expiration Date
Abstract
The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.
Core Innovation
The invention relates to selecting a lactic acid bacterial strain for preventing or treating bone loss in a mammalian individual. The selected strain is Lactobacillus reuteri JCM 1112 (SEQ ID NO: 1) and is identified by the presence of specific nucleotides at defined positions relative to the genome of Lactobacillus reuteri JCM 1112.
The disclosure links the effectiveness of the selected Lactobacillus reuteri strain to reestablishing an altered gut microbial community and/or restoring the microbial community toward a control state. It contrasts L. reuteri ATCC PTA 6475 with a non-selected near-identical strain L. reuteri ATCC PTA 4659, and characterizes PTA 4659 as anti-inflammatory but ineffective for preventing or treating bone loss.
The patent further broadens the prevention or treatment use to populations at risk of bone loss, including menopausal women, hysterectomy patients, diabetics, and osteopenic individuals. The disclosure also describes combinations with vitamin D and hormone therapies, and associates the selected approach with osteoclast marker (TRAP5) being returned to baseline and with improved distal femur bone volume fraction (BV/TV).
Claims Coverage
The partial content provides one independent claim, requiring administration of a lactic acid bacterial strain that is Lactobacillus reuteri JCM 1112 and that contains specific nucleotides at four defined base-pair positions relative to the Lactobacillus reuteri JCM 1112 (SEQ ID NO: 1) genome.
Preventing or treating bone loss by administering a specified lactic acid bacterial strain
A method for preventing or treating bone loss comprising administering to an individual in need thereof a lactic acid bacterial strain, wherein the lactic acid bacterial strain is Lactobacillus reuteri JCM 1112.
Four-position nucleotide requirement relative to Lactobacillus reuteri JCM 1112
The lactic acid bacterial strain harbors a nucleotide relative to the genome of Lactobacillus reuteri JCM 1112 (SEQ ID NO: 1) in all of the following four positions: C in base pair 271391, G in base pair 453538, G in base pair 529228, and C in base pair 599338.
Across the provided independent claim, the inventive coverage centers on administering Lactobacillus reuteri JCM 1112 and restricting the strain to those having the four specified nucleotides at the four defined base-pair positions relative to the Lactobacillus reuteri JCM 1112 genome.
Stated Advantages
Suppressing ovx-induced bone loss with osteoclast marker (TRAP5) returned to baseline.
Shifting jejunal and ileal microbiota toward a control state by reestablishing an altered gut microbial community and/or restoring the microbial community.
Preventing or treating bone loss in populations at risk of bone loss, including menopausal women, hysterectomy patients, diabetics, and osteopenic individuals.
Documented Applications
Preventing or treating bone loss in an individual in need thereof via administration of the defined Lactobacillus reuteri strain.
Use in populations at risk of bone loss, including menopausal women, hysterectomy patients, diabetics, and osteopenic individuals.
Use in combination with vitamin D and hormone therapies.
Interested in licensing this patent?